Exploration of Targeted Anti-tumor Therapy

Table 1. Baseline characteristics across included studies.

Study	Design	Intervention	Control	Age (Intervention)	Age (Control)	Baseline PSA (Intervention)	Baseline PSA (Control)	ECOG-0 n (%)	ECOG-1 n (%)	ECOG-2 n (%)	ECOG-3 n (%)
Shimura, 2020	Retrospective cohort	2-weekly docetaxel (25–35 mg/m²)	3-weekly docetaxel (60–75 mg/m²)	67.0 (8.08)	70.8 (8.33)	301.0 (526.9)	280.1 (499.8)	0 (0)/0 (0)	20 (76.9)/17 (65.4)	4 (15.4)/8 (30.8)	2 (7.7)/1 (3.8)
Hervonen, 2012	RCT	3-weekly docetaxel (75 mg/m²)	2-weekly docetaxel (50 mg/m²)	70.0 (8.82)	68.0 (7.98)	109.0 (200.3)	98.0 (310.6)	NR	25 (65)/20 (51)	NR	NR
Martinez-Recio, 2022	Retrospective study	3-weekly docetaxel (75 mg/m²)	2-weekly docetaxel (50 mg/m²)	69.0 (7.53)	78.0 (5.06)	888.3 (631.5)	646.8 (564.2)	NR	NR	NR	NR
Berthold, 2008	Retrospective study	3-weekly docetaxel + mitoxantrone	Weekly docetaxel + mitoxantrone	64.8 (0.61)	65.5 (0.42)	620.2 (459.7)	224.8 (132.3)	NR	NR	NR	NR
Kim, 2017	Retrospective study	3-weekly docetaxel	Biweekly docetaxel	69.1 (7.86)	66.5 (6.01)	34.7 (NR)	31.1 (NR)	NR	NR	NR	NR
Lehtonen, 2022	Phase III trial	3-weekly docetaxel	Biweekly docetaxel	66.8 (7.24)	67.5 (7.76)	116 (Median)	109 (Median)	NR	NR	NR	NR
Petrioli, 2011	Phase II RCT	Weekly docetaxel	3-weekly docetaxel	69.3 (7.29)	69.8 (6.42)	90.0 (39.5)	99.0 (57.5)	8 (21.6)/11 (31.1)	29 (78.4)/24 (68.6)	NR	NR
Yuk, 2024	Retrospective cohort	Weekly docetaxel	Biweekly/Triweekly docetaxel	72.4 (7.9)	70.2–68.2 (8.8–8.9)	237.1 (87.4)	714.3–778.7 (207.8–144)	11 (28.9)/17 (52.0)	8 (21.1)/16 (39.0)	4 (10.5)/0 (0)	15 (39.5)/8 (19.5)
Kellokumpu-Lehtinen, 2013	Phase III RCT	2-weekly docetaxel	3-weekly docetaxel	67.8 (7.27)	68.8 (7.80)	119.3 (42.15)	112.1 (36.03)	NR	NR	NR	NR
Samar, 2020	Retrospective study	2-weekly docetaxel	3-weekly docetaxel	67.3 (8.9)	67.3 (8.9)	236.2 (126.3)	294.1 (520.9)	5 (55.5)/3 (20.0)	3 (33.3)/8 (53.3)	1 (11.1)/2 (13.3)	0 (0)/2 (13.3)
Sayin, 2022	Retrospective study	3-weekly docetaxel	Weekly docetaxel	NR	NR	NR	NR	35 (89.7)/8 (20.0)	NR	NR	NR

Return to article view

RCT: randomized controlled trial; ECOG: Eastern Cooperative Oncology Group; PSA: prostate-specific antigen; NR: not reported; mg/m²: milligrams per square meter.

Supplementary materials

The supplementary material for this article is available at: https://www.explorationpub.com/uploads/Article/file/1002360_sup_1.pdf.

Declarations

Author contributions

SR: Conceptualization, Resources, Data curation, Software, Formal analysis, Supervision, Validation, Investigation, Methodology, Writing—original draft, Project administration, Writing—review & editing. FS: Project administration. KAR: Data curation, Formal analysis, Visualization. ZB, AOS, UH, UA, WU, FB, OA, MK: Writing—original draft. AL: Writing—original draft, Writing—review & editing. All authors read and approved the submitted version.

Conflicts of interest

The authors declare that there are no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

The database for this systematic review was sourced online from databases listed in the methods. Additional data are available from the corresponding author upon request to any qualified researcher.

Funding

Not applicable.

Copyright

Publisher’s note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

Rath S, Lal A, Hasan A, Ali M, Sultan L, Khan M, et al. Long-Term Mortality Trends From Prostate Cancer and Associated Second Malignancies in the U.S., 1999 to 2023: Implications for Survivorship Care. Clin Genitourin Cancer. 2025;23:102428. [DOI] [PubMed]

Sayegh N, Swami U, Agarwal N. Recent Advances in the Management of Metastatic Prostate Cancer. JCO Oncol Pract. 2022;18:45–55. [DOI] [PubMed]

Van Poppel H. Recent docetaxel studies establish a new standard of care in hormone refractory prostate cancer. Can J Urol. 2005;12 Suppl 1:81–5. [PubMed]

Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al.; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12. [DOI] [PubMed]

Lendorf ME, Petersen PM, Svendsen AS, Lindberg H, Brasso K. Effectiveness of Docetaxel for Metastatic Hormone-sensitive Prostate Cancer in Clinical Practice. Eur Urol Open Sci. 2021;24:25–33. [DOI] [PubMed] [PMC]

Sinibaldi VJ. Docetaxel treatment in the elderly patient with hormone refractory prostate cancer. Clin Interv Aging. 2007;2:555–60. [DOI] [PubMed] [PMC]

Martinez-Recio S, Perez-Wert JP, Martinez-Fdez S, Jimenez-Bou D, Ruiz-Gutierrez I, Peña J, et al. Comparison of 2-Weekly and 3-Weekly Dosing of Docetaxel in Metastatic Prostate Cancer. Clin Genitourin Cancer. 2022;20:363–70. [DOI] [PubMed]

Yuk HD, Kim M, Keam B, Ku JH, Kwak C, Jeong CW. Weekly versus 2-weekly versus 3-weekly docetaxel to treat metastatic castration-resistant prostate cancer. Prostate Int. 2024;12:219–23. [DOI] [PubMed] [PMC]

Kellokumpu-Lehtinen P, Harmenberg U, Joensuu T, McDermott R, Hervonen P, Ginman C, et al. 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol. 2013;14:117–24. [DOI] [PubMed]

10.

Wang L, Li C, Zhao Z, Li X, Tang C, Guan Z, et al. Comparison of doublet and triplet therapies for metastatic hormone-sensitive prostate cancer: A systematic review and network meta-analysis. Front Oncol. 2023;13:1104242. [DOI] [PubMed] [PMC]

11.

Salanti G, Higgins JPT, Ades AE, Ioannidis JPA. Evaluation of networks of randomized trials. Stat Methods Med Res. 2008;17:279–301. [DOI] [PubMed]

12.

Feyerabend S, Saad F, Li T, Ito T, Diels J, Sanden SV, et al. Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis. Eur J Cancer. 2018;103:78–87. [DOI] [PubMed]

13.

Cochrane Handbook for Systematic Reviews of Interventions [Internet]. The Cochrane Collaboration; c2026 [cited 2025 Jan 11]. Available from: https://training.cochrane.org/handbook

14.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. [DOI] [PubMed] [PMC]

15.

Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. [DOI] [PubMed]

16.

The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [Internet]. Ottawa Hospital Research Institute; c2025 [cited 2026 Jan 3]. Available from: https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp

17.

Hervonen P, Joensuu H, Joensuu T, Ginman C, McDermott R, Harmenberg U, et al. Biweekly docetaxel is better tolerated than conventional three-weekly dosing for advanced hormone-refractory prostate cancer. Anticancer Res. 2012;32:953–6. [PubMed]

18.

Lehtonen M, Sormunen J, Luukkaala T, Marttila T, McDermott R, Joensuu T, et al. 2-weekly versus 3-weekly docetaxel for metastatic castration-resistant prostate cancer: complete quality of life results from the randomised, phase-III PROSTY trial. Acta Oncol. 2022;61:963–71. [DOI] [PubMed]

19.

Petrioli R, Pascucci A, Conca R, Chiriacò G, Francini E, Bargagli G, et al. Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study. Br J Cancer. 2011;104:613–9. [DOI] [PubMed] [PMC]

20.

Berthold DR, Pond GR, de Wit R, Eisenberger M, Tannock IF; Investigators T3; TAX 327 Investigators. Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol. 2008;19:1749–53. [DOI] [PubMed]

21.

Kim HS, Lee JY, Lee SJ, Lim HY, Sung HH, Jeon HG, et al. A retrospective feasibility study of biweekly, reduced-dose docetaxel in Asian patients with castrate-resistant, metastatic prostate cancer. BMC Urol. 2017;17:63. [DOI] [PubMed] [PMC]

22.

Samar A, Tiwari S, Subramanian S, Joshi N, Sejpal J, Khan MA, et al. A Multicentric, Retrospective Efficacy and Safety Study of Nanosomal Docetaxel Lipid Suspension in Metastatic Castration-Resistant Prostate Cancer. Prostate Cancer. 2020;2020:4242989. [DOI] [PubMed] [PMC]

23.

Sayin M, Celenkoglu G. Comparison of Weekly Low Dose Docetaxel with the Standard Protocol in Hormone-resistant Metastatic Prostate Cancer. J Coll Physicians Surg Pak. 2022;32:1026–32. [DOI] [PubMed]

24.

Shimura Y, Suga Y, Itai S, Iwamoto H, Takezawa Y, Yaegashi H, et al. Comparison of Tolerability Between 2-Weekly and 3-Weekly Docetaxel Regimen in Castration-resistant Prostate Cancer. Anticancer Res. 2020;40:4291–7. [DOI] [PubMed]

25.

Neto AS, Tobias-Machado M, Kaliks R, Wroclawski ML, Pompeo ACL, Giglio AD. Ten years of docetaxel-based therapies in prostate adenocarcinoma: a systematic review and meta-analysis of 2244 patients in 12 randomized clinical trials. Clin Genitourin Cancer. 2011;9:115–23. [DOI] [PubMed]

26.

Francini E, Petrioli R, Rossi G, Laera L, Roviello G. PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatments for patients with metastatic castration-resistant prostate cancer: an analysis of 22 trials. Tumour Biol. 2014;35:10601–7. [DOI] [PubMed]

27.

Petrylak DP, Tangen CM, Hussain MHA, Jr PNL, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–20. [DOI] [PubMed]

28.

Taplin M. Biochemical (Prostate-Specific Antigen) Relapse: An Oncologist’s Perspective. Rev Urol. 2003;5 Suppl 2:S3–13. [PubMed] [PMC]

29.

Gajra A, Zemla TJ, Jatoi A, Feliciano JL, Wong ML, Chen H, et al. Time-to-Treatment-Failure and Related Outcomes Among 1000+ Advanced Non-Small Cell Lung Cancer Patients: Comparisons Between Older Versus Younger Patients (Alliance A151711). J Thorac Oncol. 2018;13:996–1003. [DOI] [PubMed] [PMC]

30.

Kushnir I, Mallick R, Ong M, Canil C, Bossé D, Koczka K, et al. Docetaxel dose-intensity effect on overall survival in patients with metastatic castrate-sensitive prostate cancer. Cancer Chemother Pharmacol. 2020;85:863–8. [DOI] [PubMed]

31.

van Eijk M, Vermunt MAC, van Werkhoven E, Wilthagen EA, Huitema ADR, Beijnen JH. The influence of docetaxel schedule on treatment tolerability and efficacy in patients with metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials. BMC Cancer. 2022;22:104. [DOI] [PubMed] [PMC]